Scope of our work

Scope

The Group aims to cover interventions for the whole range of neuromuscular disease. In 2008 we have begun to develop a strategy for covering tests of diagnostic accuracy for neuromuscular disease. Anyone interested in contributing to reviews of tests of diagnostic accuracy should contact the Managing Editor.
We consider neuromuscular disease to include:
1. muscle diseases;
2. neuromuscular junction disorders;
3. peripheral neuropathy;
4. motor neuron disorders;
5. other disorders related to neuromuscular disease;
6. generic treatments for neuromuscular disease;
7. 'orphan' diseases, which affect the peripheral and central nervous system.

We include all aspects of management, including:
1. prevention;
2. acute management;
3. psychosocial interventions (such as stress relaxation, meditation and biofeedback);
4. complementary medicine;
5. rehabilitation.

There are areas of known or potential shared interests, with the following entities:
Airways Group
Anaesthesia Group
Back Group
Depression Anxiety and Neurosis Group
Ear, Nose & Throat Group
Metabolic and Endocrine Disorders Group
Infectious Diseases Group
Injuries Group
Pain, Palliative and Supportive Care Group
Musculoskeletal Group
Skin Group
Offers of protocols/reviews on subjects which may be shared with any of the above Groups are resolved by negotiation with the relevant Co-ordinating Editors before the protocol or review is accepted.
The following titles have been or are being prepared collaboratively:
- Non-depolarising muscle relaxants for myasthenic patients undergoing transsternal thymectomy - a collaboration between the Cochrane Anaesthesia Review Group and the Cochrane Neuromuscular Disease Group (Cordero Escobar I, Espinaco Valdés J, Gutierrez Rojas AR, Jimenez Paneca RE, Parisi López N. Nondepolarizing muscle relaxants for surgery in myasthenic patients. (Protocol) Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD006582. DOI: 10.1002/14651858.CD006582.).
- Aldose reductase inhibitors for treating diabetic polyneuropathy - a collaboration between the Cochrane Neuromuscular Disease Group and the Metabolic and Endocrine Disorders Group (Chalk C, Benstead TJ, Moore F. Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD004572. DOI: 10.1002/14651858.CD004572.pub2).
- Glycemic control for preventing and treating diabetic neuropathy - a collaboration between the Cochrane Neuromuscular Disease Group and the Metabolic and Endocrine Disorders Group.
Duloxetine for treating painful neuropathy or chronic pain. Lunn MPT, Hughes RAC, Wiffen PJ - a collaboration between the Cochrane Neuromuscular Disease Group and the Pain, Palliative and Supportive Care Group.